ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL) | Rumor.io

Zentalis Pharmaceuticals

ZNTL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,909

Bullish sentiment (50-day avg)58%

Price to earnings ratio-1.36

Market capitalization246.1M

Earnings per share-1.96

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-137.1M

Social

What share of all stock conversation is about ZNTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 17

Zentalis Pharmaceuticals' ($ZNTL) stock increased by 13.1% to $5.17, indicating renewed buyer interest in the pharmaceutical space.
Mizuho has an Outperform rating and a $8 price target for $ZNTL, highlighting 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
Data from the DENALI Part 1b study of azenosertib show long-term survival benefits in patients with Cyclin E1-positive platinum-resistant ovarian cancer, according to Zentalis Pharmaceuticals.

Generated by AI

Sentiment

Of the messages about ZNTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	25% -50	87.03% +15.57
Bearish	100%	100% new	75% +50	12.97% -15.57

Bullish· Jun 30

Zentalis Pharmaceuticals' ($ZNTL) DENALI Part 2a study in platinum-resistant ovarian cancer showed encouraging interim results.
Guggenheim maintained a Buy rating on $ZNTL with a target price of $10, up from $6, following the positive study results.
$ZNTL has broken out of its previous range, with multiple analysts and traders noting a significant increase in price.

Bearish· Apr 13

$ZNTL is likely to continue falling, with a possible target of $5.50, as it struggles to hold above this level.
The stock's recent price action is indicative of a potential pump and dump scheme, with the company possibly announcing an offering to raise cash.
$ZNTL is overbought and due for a retracement, with a possible bounce to $4.50, although the long-term outlook remains bearish.

Generated by AI

Topics

Of the messages about ZNTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	34.23%
Announcements	—	—	0%	61.99%
Analysts	—	—	100%	3%
Controversies	—	—	0%	0.79%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Apr 10

Zentalis Pharmaceuticals' stock surges after the company announces the pivotal dose selection of 400mg QD 5:2 azenosertib monotherapy in cyclin E1-positive platinum-resistant ovarian cancer.
The DENALI study shows a clearly differentiated response rate and a comparable safety profile, driving significant investor optimism and a major clinical development catalyst.
Guggenheim raises its price target to $10, signaling a major re-rating of the stock, and insider buying activity is detected, further fueling the high-conviction move.

Technical Analysis· Jun 30

Zentalis Pharmaceuticals ($ZNTL) has experienced a clean breakout, indicating a potential upward trend.
The breakout is characterized by a sharp increase in price, suggesting increased investor interest and momentum.
Technical analysts are monitoring $ZNTL for further signs of strength, including consolidation and potential retests of key levels.

Generated by AI

Community

Of the messages about ZNTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	85.71%	13.41%	23.14%
Newcomers	14.29%	14.29%	86.59%	76.86%

Regulars· Apr 10

The stock has shown significant growth, increasing from $1.46 to $6.50, and regulars are now waiting for an offering.
The stock has a heavy float and is up 52%, with regulars setting bids to rebuy and others being cautious due to the Iran situation.
The stock is showing strong momentum, with buyers still favoring the upside, and a potential break above resistance at $6.50 could be significant.

Newcomers· Jun 30

Many users are celebrating a breakout in $ZNTL, with several noting that the stock is "finally moving".
The breakout is seen as a positive development, with users expressing enthusiasm and hope that the stock will hold its gains.
Some users are speculating that the breakout may be a sign of a larger trend or that the stock is gaining momentum.

Generated by AI

News

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - Zentalis Pharmaceuticals (NASDA

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

13d agoBenzinga

Also Discussed

Investors talking about ZNTL also mention

#	Name	Attention
1	Erasca Inc.ERAS	0%0
2	Invesco Variable Rate Investment Grade ETFVRIG	0%new
3	LiqTech International Inc.LIQT	0%new
4	MKDWELL Tech Inc.MKDW	0%+0
5	Avanos Medical Inc.AVNS	0%0
6	Altrius Global Dividend ETFDIVD	0%0
7	LanzaTech Global Inc. Common StockLNZA	0%new
8	Roma Green Finance LimitedROMA	0%0
9	iShares Texas Equity ETFTEXN	0%0
10	Distribution Solutions Group, Inc.DSGR	0%0

Zentalis Pharmaceuticals, Inc.

Healthcare
Biotechnology

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways of cancer. It maintains a broad pipeline of product candidates, with an initial emphasis on validated oncology targets designed to address large patient populations. The company advances innovative therapies, including a first-in-class WEE1 inhibitor in late-stage development and biomarker-driven treatments for ovarian cancer. Zentalis Pharmaceuticals, Inc. operates within the health technology and biotechnology sectors, contributing to oncology research by pursuing small molecule approaches to improve cancer treatment options. Founded in 2014 and headquartered in San Diego, California, it dedicates efforts to groundbreaking research in clinical-stage oncology programs.

Website

Location

10275 Science Center Dr.

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about ZNTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 17

Zentalis Pharmaceuticals' ($ZNTL) stock increased by 13.1% to $5.17, indicating renewed buyer interest in the pharmaceutical space.
Mizuho has an Outperform rating and a $8 price target for $ZNTL, highlighting 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
Data from the DENALI Part 1b study of azenosertib show long-term survival benefits in patients with Cyclin E1-positive platinum-resistant ovarian cancer, according to Zentalis Pharmaceuticals.

Generated by AI

Sentiment

Of the messages about ZNTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	25% -50	87.03% +15.57
Bearish	100%	100% new	75% +50	12.97% -15.57

Bullish· Jun 30

Zentalis Pharmaceuticals' ($ZNTL) DENALI Part 2a study in platinum-resistant ovarian cancer showed encouraging interim results.
Guggenheim maintained a Buy rating on $ZNTL with a target price of $10, up from $6, following the positive study results.
$ZNTL has broken out of its previous range, with multiple analysts and traders noting a significant increase in price.

Bearish· Apr 13

$ZNTL is likely to continue falling, with a possible target of $5.50, as it struggles to hold above this level.
The stock's recent price action is indicative of a potential pump and dump scheme, with the company possibly announcing an offering to raise cash.
$ZNTL is overbought and due for a retracement, with a possible bounce to $4.50, although the long-term outlook remains bearish.

Generated by AI

Topics

Of the messages about ZNTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	34.23%
Announcements	—	—	0%	61.99%
Analysts	—	—	100%	3%
Controversies	—	—	0%	0.79%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Apr 10

Zentalis Pharmaceuticals' stock surges after the company announces the pivotal dose selection of 400mg QD 5:2 azenosertib monotherapy in cyclin E1-positive platinum-resistant ovarian cancer.
The DENALI study shows a clearly differentiated response rate and a comparable safety profile, driving significant investor optimism and a major clinical development catalyst.
Guggenheim raises its price target to $10, signaling a major re-rating of the stock, and insider buying activity is detected, further fueling the high-conviction move.

Technical Analysis· Jun 30

Zentalis Pharmaceuticals ($ZNTL) has experienced a clean breakout, indicating a potential upward trend.
The breakout is characterized by a sharp increase in price, suggesting increased investor interest and momentum.
Technical analysts are monitoring $ZNTL for further signs of strength, including consolidation and potential retests of key levels.

Generated by AI

Community

Of the messages about ZNTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	85.71%	13.41%	23.14%
Newcomers	14.29%	14.29%	86.59%	76.86%

Regulars· Apr 10

The stock has shown significant growth, increasing from $1.46 to $6.50, and regulars are now waiting for an offering.
The stock has a heavy float and is up 52%, with regulars setting bids to rebuy and others being cautious due to the Iran situation.
The stock is showing strong momentum, with buyers still favoring the upside, and a potential break above resistance at $6.50 could be significant.

Newcomers· Jun 30

Many users are celebrating a breakout in $ZNTL, with several noting that the stock is "finally moving".
The breakout is seen as a positive development, with users expressing enthusiasm and hope that the stock will hold its gains.
Some users are speculating that the breakout may be a sign of a larger trend or that the stock is gaining momentum.

Generated by AI

Zentalis Pharmaceuticals

Social

Jul 17

Bullish· Jun 30

Bearish· Apr 13

Announcements· Apr 10

Technical Analysis· Jun 30

Regulars· Apr 10

Newcomers· Jun 30

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - Zentalis Pharmaceuticals (NASDA

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair Initiates Zentalis Pharmaceuticals at Outperform

William Blair initiates Zentalis stock with outperform rating

Zentalis at Morgan Stanley conference: azenosertib push gains shape

Zentalis at Wells Fargo conference: azenosertib gains clearer path

Also Discussed

Zentalis Pharmaceuticals, Inc.

Company Information

Location

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - Zentalis Pharmaceuticals (NASDA

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair Initiates Zentalis Pharmaceuticals at Outperform

William Blair initiates Zentalis stock with outperform rating

Zentalis at Morgan Stanley conference: azenosertib push gains shape

Zentalis at Wells Fargo conference: azenosertib gains clearer path

Also Discussed

Social

Jul 17

Bullish· Jun 30

Bearish· Apr 13

Announcements· Apr 10

Technical Analysis· Jun 30

Regulars· Apr 10

Newcomers· Jun 30